Allena Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Business Update

Biotech Investing

Allena Pharmaceuticals (NASDAQ:ALNA), a late-stage, clinical biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today reported financial results for the first quarter ended March 31, 2018 and also provided a business update. As quoted in the press release: “Our accomplishments so …

Allena Pharmaceuticals (NASDAQ:ALNA), a late-stage, clinical biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today reported financial results for the first quarter ended March 31, 2018 and also provided a business update.

As quoted in the press release:

“Our accomplishments so far this year reflect our commitment to rapidly developing therapies for patients with severe metabolic and kidney-related disorders,” said Alexey Margolin, Ph.D., Chief Executive Officer of Allena Pharmaceuticals. “In the first quarter, we initiated URIROX-1 and Study 206, two late-stage trials of ALLN-177 in patients with severe oxalate disorders, for whom safe and effective new medicines are urgently needed.  Looking ahead, we are focused on advancing ALLN-177 as well as ALLN-346, our second product candidate for patients with hyperuricemia and chronic kidney disease, and remain on track to execute on our key objectives.”

Click here to read the full press release.

The Conversation (0)
Ă—